Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (251-260 of 427) with videos related to

Pageof 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2005
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myelomaM S Raab, F W Cremer, I N Breitkreutz, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 15, 2001
Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinomaY Liu, C D Sturgis, D M Grzybicki, et al.
Archives of Pathology & Laboratory Medicine|May 27, 2026
Interpretive Diagnostic Error Reduction: Guideline Update from the College of American Pathologists in Collaboration With the Association of Directors of Anatomic and Subspecialty PathologySuzanne M Dintzis, Juanita J Evans, Marisol Hernandez, et al.
Bone Marrow Transplantation|September 25, 2007
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)M Hundemer, U Klein, D Hose, et al.
American Journal of Clinical Pathology|April 22, 2006
Double slide viewing as a cytology quality improvement initiativeStephen S Raab, Chad H Stone, Chris S Jensen, et al.
Pageof 43

Showing results (251-260 of 427) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2005
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myelomaM S Raab, F W Cremer, I N Breitkreutz, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 15, 2001
Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinomaY Liu, C D Sturgis, D M Grzybicki, et al.
Archives of Pathology & Laboratory Medicine|May 27, 2026
Interpretive Diagnostic Error Reduction: Guideline Update from the College of American Pathologists in Collaboration With the Association of Directors of Anatomic and Subspecialty PathologySuzanne M Dintzis, Juanita J Evans, Marisol Hernandez, et al.
Bone Marrow Transplantation|September 25, 2007
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)M Hundemer, U Klein, D Hose, et al.
American Journal of Clinical Pathology|April 22, 2006
Double slide viewing as a cytology quality improvement initiativeStephen S Raab, Chad H Stone, Chris S Jensen, et al.
Pageof 43